Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Nov;6(11):1210-1211.
doi: 10.1158/2159-8290.CD-16-1056.

Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?

Alexandra Snyder  1   2 , Jedd D Wolchok  3   4   5   6
Affiliations
Case Reports

Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?

Alexandra Snyder et al. Cancer Discov. 2016 Nov.

Abstract

Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 blockade. Cancer Discov; 6(11); 1210-11. ©2016 AACR.See related article by Johanns et al., p. 1230.

PubMed Disclaimer

Conflict of interest statement

Alexandra Snyder has received a commercial research grant from Bristol-Myers Squibb; she serves as a consultant for Bristol-Myers Squibb and Neon. Jedd D. Wolchok has received a commercial research grant from Bristol-Myers Squibb, Merck, Medimmune and Genentech; he serves as a consultant for the same.

Comment on

References

    1. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine. 2014;371(23):2189–99. - PMC - PubMed
    1. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207–11. - PMC - PubMed
    1. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational Landscape Determines Sensitivity to Programmed Cell Death-1 Blockade in Non-Small Cell Lung Cancer. Science. 2015;348(6230):124–8. - PMC - PubMed
    1. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. - PMC - PubMed
    1. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine. 2015;372(26):2509–20. - PMC - PubMed

MeSH terms

LinkOut - more resources